US stocks surged | YARTEMLEA drug approved by FDA Omeros Pharmaceuticals (OMER.US) soared nearly 65%

According to the Financial Intelligence APP, on Wednesday, Omeros Corporation (OMER.US) surged nearly 65%, hitting a new high for the year at $14.38 USD. In terms of news, the company announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA (narsoplimab) for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), a usually fatal complication of stem cell transplantation caused by activation of the lectin pathway of the complement system. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2 (the effector enzyme of the lectin pathway), preventing pathway activation while preserving important classic and alternative complement functions in host defense. YARTEMLEA has been approved for use in adults and children aged two and above.